Reviva Pharmaceuticals Holdings, Inc. RVPH 深 滬
等待開盤 03-26 09:30:00 美东时间
0.8285
+0.002
+0.18%
華盛通- 最 高0.851
- 今 開0.851
- 成交量 53.49万股
- 最 低 0.8004
- 昨 收 0.827
- 總市值 1054.43万
- 52周最高 23.20
- 市盈率 靜 --
- 換手率 4.20%
- 52周最低 0.6697
- 委 比 98.19%
- 總股本 1272.70万
- 歷史最高 302.00
- 量 比 0.18
- 振 幅 6.12%
- 歷史最低 0.00
- 每 手 1
- 風險率 4.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Behind The Drop In Reviva Pharmaceuticals Stock?
Reviva Pharmaceuticals shares are tumbling Thursday after pricing a $10 million public offering of over 6 million shares at $1.50 per share.
03-20 00:49
Reviva Pharmaceuticals Holdings shares are trading lower after the company announced a proposed public offering.
Reviva Pharmaceuticals Holdings shares are trading lower after the company anno...
03-19 04:17
Reviva Pharmaceuticals Commences Common Stock Offering; Terms Undisclosed
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system
03-19 04:11
D. Boral Capital Downgrades Reviva Pharmaceuticals to Hold
D. Boral Capital analyst Jason Kolbert downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
03-06 05:39
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
Shares of pharmaceutical companies are trading lower amid overall market weakne...
03-06 03:56
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) stock rose 17.6% to $5.88 during Wednes...
03-04 20:05
Reviva Pharmaceuticals Publishes Data From RECOVER Phase 3 Clinical Study Of Brilaroxazine For Treatment Of Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system
01-08 21:02
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Reviva Pharmaceuticals Provides Update, Written Feedback From FDA Pre-NDA Meeting, Includes A Recommendation To Conduct A Second Phase 3 Trial To Generate Additional Efficacy And Safety Data Prior To NDA Submission Of Brilaroxazine For The Treatment Of Schizophrenia; Initiation Of RECOVER-2 Registrational Trial Planned In H1 2026
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of
2025-12-23 21:12
Reviva Pharmaceuticals GAAP EPS of -$0.06
Reviva Pharmaceuticals press release (RVPH): Q3 GAAP EPS of -$0.06. As of September 30, 2025, the Company’s cash and cash equivalents totaled approximately $13.2 million compared to approximately $13....
2025-11-14 05:59
